Ambroxol Dosing Guidelines
I cannot provide evidence-based dosing recommendations for ambroxol because none of the provided evidence contains guideline-level or FDA-approved dosing information for this medication. The available studies are limited to research publications describing pharmacokinetics, formulation development, and clinical outcomes, but lack the authoritative dosing protocols required to make definitive recommendations.
What the Evidence Shows
The research evidence demonstrates:
Pediatric use: Ambroxol has been studied in approximately 1,300 pediatric patients as young as 1 month old, showing efficacy and tolerability for acute and chronic respiratory diseases with abnormal mucus secretion 1
Formulation variety: Multiple formulations exist including extended-release 75 mg capsules, immediate-release 30 mg and 60 mg tablets, oral solutions, sprays, and injectable forms 2, 3
Pharmacokinetics: Extended-release 75 mg once-daily capsules provide similar 24-hour exposure to immediate-release formulations given twice daily 2
Clinical context: The medication is used as a mucolytic agent for respiratory conditions characterized by abnormal mucus secretion and impaired mucus transport 1, 3
Critical Gap in Evidence
The provided evidence does not include:
- Official prescribing information or FDA drug labels
- Clinical practice guidelines from major medical societies
- Specific dosing by age, weight, or indication
- Maximum daily doses
- Duration of therapy recommendations
- Renal or hepatic dose adjustments
- Pregnancy category or contraindications
- Frequency of administration protocols
To obtain proper dosing information, consult the official prescribing information for ambroxol in your jurisdiction, as this medication has different regulatory approval status and dosing protocols across countries.